These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33544347)

  • 21. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.
    Rana S; Powe CE; Salahuddin S; Verlohren S; Perschel FH; Levine RJ; Lim KH; Wenger JB; Thadhani R; Karumanchi SA
    Circulation; 2012 Feb; 125(7):911-9. PubMed ID: 22261192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical value of PlGF and the sFlt1/PlGF ratio in the management of hypertensive pregnancy disorders: A retrospective real-world study in China.
    Yang H; Guo F; Guo Q; Wang Y; He P; Zhang H; Wang S
    Clin Chim Acta; 2022 Mar; 528():90-97. PubMed ID: 35104464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placental Angiogenic Factors Are Associated With Maternal Thyroid Function and Modify hCG-Mediated FT4 Stimulation.
    Korevaar TI; Steegers EA; de Rijke YB; Visser WE; Jaddoe VW; Visser TJ; Medici M; Peeters RP
    J Clin Endocrinol Metab; 2015 Oct; 100(10):E1328-34. PubMed ID: 26204137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy.
    Palm M; Basu S; Larsson A; Wernroth L; Åkerud H; Axelsson O
    Acta Obstet Gynecol Scand; 2011 Nov; 90(11):1244-51. PubMed ID: 21568945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus.
    Nuzzo AM; Giuffrida D; Moretti L; Re P; Grassi G; Menato G; Rolfo A
    Sci Rep; 2021 Jan; 11(1):2312. PubMed ID: 33504861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal angiogenic profile in pregnancies that remain normotensive.
    Faupel-Badger JM; Staff AC; Thadhani R; Powe CE; Potischman N; Hoover RN; Troisi R
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):189-93. PubMed ID: 21641103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
    Wikström AK; Larsson A; Eriksson UJ; Nash P; Nordén-Lindeberg S; Olovsson M
    Obstet Gynecol; 2007 Jun; 109(6):1368-74. PubMed ID: 17540809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Heinonen S; Hämäläinen E; Pulkki K; Romppanen J; Laivuori H;
    Pregnancy Hypertens; 2018 Oct; 14():252-259. PubMed ID: 29803331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas
    Black C; da Silva Costa F
    Methods Mol Biol; 2018; 1710():9-26. PubMed ID: 29196991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble Flt1 and placental growth factor are novel determinants of newborn thyroid (dys)function: the generation R study.
    Korevaar TI; Steegers EA; Schalekamp-Timmermans S; Ligthart S; de Rijke YB; Visser WE; Visser W; de Muinck Keizer-Schrama SM; Hofman A; Hooijkaas H; Bongers-Schokking JJ; Russcher H; Tiemeier H; Jaddoe VW; Visser TJ; Medici M; Peeters RP
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1627-34. PubMed ID: 24885632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction.
    Lorenz-Meyer LA; Frank L; Sroka D; Busjahn A; Henrich W; Verlohren S
    Pregnancy Hypertens; 2022 Jun; 28():149-155. PubMed ID: 35453103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes.
    Cohen AL; Wenger JB; James-Todd T; Lamparello BM; Halprin E; Serdy S; Fan S; Horowitz GL; Lim KH; Rana S; Takoudes TC; Wyckoff JA; Thadhani R; Karumanchi SA; Brown FM
    Hypertens Pregnancy; 2014 Feb; 33(1):81-92. PubMed ID: 24354578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic factors for the prediction of preeclampsia in high-risk women.
    Moore Simas TA; Crawford SL; Solitro MJ; Frost SC; Meyer BA; Maynard SE
    Am J Obstet Gynecol; 2007 Sep; 197(3):244.e1-8. PubMed ID: 17826405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
    Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
    Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.